The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Clinical trial NCT06140576 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06140576
- Sponsor
- Zhejiang Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-30
- Primary completion
- 2025-12-31
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.